newsfilter
← Earnings
Earnings Releases·

Annexon — Third Quarter 2026 Earnings Summary

Annexon reported a net loss of $51.2 million for the third quarter of 2026, with cash and short-term investments totaling $213.4 million as of September 30, 2026. The company advanced its tanruprubart program for Guillain-Barré syndrome, with a U.S. Biologics License Application submission anticipated in the fourth quarter and an EU Marketing Authorisation Application currently under review. For its vonaprument program targeting geographic atrophy, the Phase 3 ARCHER II trial is on track to assess its primary endpoint at month 15 in the fourth quarter of 2026. Additionally, Annexon secured a strategic credit facility of up to $200 million and appointed new leadership to its board and scientific advisory teams to support these registrational programs.

Company
ANNEXON INC
Sector
Healthcare
Industry
Biotechnology